Arthur Aung @Arthur_Aung

Hematology Oncology Fellow | Northwell Health Northshore/LIJ Hospital New York, USA Joined July 2012

Tweets

132
Followers

248
Following

1K
Likes

138

Jafar Najafov @JafarNajafov

5 days ago

Claude can now break down papers like an MIT researcher. Here are 10 insane Claude prompts that turn dense research papers into simple summaries, diagrams, limitations, experiments, and future research ideas in minutes (Save this)

8 49 162 23K 341

View Details

Arthur Aung @Arthur_Aung

a week ago

@JCOOP_ASCO One question that emerged from this work: Should our assessment of tolerability extend beyond adverse events to include a patient's ability to remain on therapy long enough to derive benefit? #ProjectOptimus #LCSM

0 0 1 61 0

View Details

Arthur Aung @Arthur_Aung

a week ago

Excited to share our systematic review and meta-analysis of standard- versus reduced-dose sotorasib in KRAS G12C-mutated NSCLC, now published in @JCOOP_ASCO Reduced dosing did not appear to substantially compromise efficacy, supporting dose optimization efforts aligned with FDA Project Optimus. Grateful to my coauthors for their contributions to this work. @NagashreeSeeth1 @DivyaReddyMD @KRASKickers #KRAS #ProjectOptimus #LCSM ascopubs.org/doi/10.1200/OP…

1 4 9 502 0

View Details

Arthur Aung @Arthur_Aung

a week ago

Completely agree. Tolerability is more than adverse events. If reduced toxicity allows patients to stay on treatment longer without compromising target inhibition, it may become part of the efficacy pathway itself. Grateful to @HannahRAbrams for highlighting this concept and to @NagashreeSeeth1 for her mentorship on the work behind these observations.

Hannah Abrams, MD @HannahRAbrams

a week ago

In this regard, drugs like Zofran, interventions like exercise, etc, are some of the most powerful cancer Rx we have. So kudos @Arthur_Aung on this study - higher upfront dose intensity is not always most effective if can’t consistently deliver it safely!

0 1 3 508 0

0 0 1 105 0

View Details

Arthur Aung @Arthur_Aung

a week ago

@HannahRAbrams @JCOOP_ASCO @KRASKickers @NagashreeSeeth1 Thank you @HannahRAbrams. It raises an interesting question: should our assessment of tolerability extend beyond adverse events to include a patient's ability to remain on therapy long enough to derive benefit?

0 1 2 995 0

View Details

Arthur Aung @Arthur_Aung

a week ago

Excited to see this work presented at #ASCO26. Patients with pre-existing autoimmune disease remain underrepresented in immunotherapy trials, and real-world data are critical to informing treatment decisions. Looking forward to seeing the results and discussion. @NehemiasGuevar5 @dominicandoc2 @oncodaily

Abner Antonio Murray, MD PhD @dominicandoc2

a week ago

0 2 5 1K 1

0 2 2 467 0

View Details

Abner Antonio Murray, MD PhD @dominicandoc2

a week ago

Congrats to @NehemiasGuevar5 & team #ASCO26 Key takeaways for oncologists: 🔹 Autoimmune disease ≠ automatic exclusion from ICIs 🤔 Requires careful toxicity monitoring & patient selection 🤝 Strong oncology + rheumatology collaboration is critical 🔹 Shared decision-making remains essential Important real-world data for everyday practice 💉🫁 #Immunotherapy @ASCOTECAG @hemeoncfellow @HemOncFellows @ASCO

FlorezLab @Florez_Lab

a week ago

Join @NehemiasGuevar5 at #ASCO26 as he presents Poster 81: “Survival outcomes in individuals with cancer and pre-existing autoimmune disease receiving immune checkpoint inhibitors 📍 Hall A 🗓 June 1 ⏰ 9:00 AM–12:00 PM

0 4 6 866 1

0 2 5 1K 1

View Details

Arthur Aung @Arthur_Aung

2 weeks ago

Thank you @NarjustFlorezMD for building such a supportive community for trainees and early-career oncologists. It’s a great reminder of how much mentorship and community can shape our careers. @NehemiasGuevar5 #ASCO26

Narjust Florez, MD, FASCO @NarjustFlorezMD

2 weeks ago

My joy and pride - the community that I once created so nobody will feel as isolated as once did. At our yearly lunch at #ASCO26

1 8 56 3K 1

0 2 8 502 0

View Details

Ashish Samaddar, MD @SamaddarMD

3 weeks ago

What environmental factors may contribute to lung cancer risk beyond smoking? Looking forward to presenting our #ASCO26 poster on ambient carbon tetrachloride exposure and lung cancer incidence in the U.S. Abstract: asco.org/abstracts-pres… @NagashreeSeeth1 @NorthwellHealth

1 2 4 228 0

View Details

Arthur Aung @Arthur_Aung

2 weeks ago

As oncology becomes increasingly complex, patient education is more important than ever. I'm grateful for the opportunity to work with @cancerGRACE on a patient education series focused on #ThyroidCancer, covering 🧬 Targeted therapies 🩺 Treatment pathways 📈 Management of recurrent thyroid cancer Video 30-32 youtube.com/playlist?list=… Translating rapidly evolving science into practical information for patients and caregivers remains an essential part of delivering high-quality cancer care. If you're in Chicago for #ASCO26, join us at the GRACE reception: 📍 Beatrix North 📅 May 29 🕖 7 PM #ThyroidCancer #PatientEducation #ASCO26 @NagashreeSeeth1 @JackWestMD @AmyBickleman @NehemiasGuevar5 @oncodaily @EliLillyandCo @ASCOTECAG

1 2 6 335 0

View Details

Nagashree Seetharamu, MD, FASCO @NagashreeSeeth1

2 weeks ago

Now focusing on the rapid oral abstract head and neck cancers (Monday 6/1 at 4:30 PM CT)- a fascinating line up featuring novel therapeutics and strategies-hinting towards a brighter future

0 1 8 525 1

View Details

Liang Chang @liangc_science

2 months ago

I used a team of ~30 AI agents to analyze 57,603 ASCO Abstracts between 2016-2025. Here are my top 6 learnings on the past decade of oncology open.substack.com/pub/liangchang…

1 7 29 21K 31

View Details

Nehemias Guevara-Rodriguez @NehemiasGuevar5

4 weeks ago

Excited to share our new publication with @NarjustFlorezMD @MImbimbo1 @COlazagasti on lung cancer diagnosed during pregnancy — a rare and highly complex clinical scenario requiring multidisciplinary care. frontiersin.org/journals/oncol…

1 6 16 3K 0

View Details

Abner Antonio Murray, MD PhD @dominicandoc2

a month ago

Conference season is upon us with poster sessions, #oralabstracts, and #grandrounds on the horizon! To help prepare, we wrote this #ASCOconnection article: 🔗 The High-Stakes Talk 🗣️ @jennifermarksmd @ASCO In the piece, we share practical strategies to: 🔹 Lead with the core message 🔹 Make the “so what” clear 🔹 And more Because strong science should be easy to understand, discuss, remember, and carry forward. 🙋🏾‍♂️What is the best presentation advice you have received or the one lesson you wish you had learned earlier? connection.asco.org/do/high-stakes… #Oncology #MedEd #ASCOtips #PresentationTips #PosterPresentation #ResearchTalks @hemeoncfellow @HemOncFellows @SNMA @LmsaNational @ASCOTECAG @OncoAlert @oncodaily

1 9 19 3K 9

View Details

#TumorBoardTuesday @TumorBoardTues

a month ago

#TumorBoardTuesday 🫁 Early-stage #NSCLC is no longer just surgery ➕ chemo: Molecular testing now shapes curative-intent Tx decisions 🧬 📢Join us Tuesday, 05-05-26 at 8PM ET as @NarjustFlorezMD & @NehemiasGuevar5 🗣️EGFR+ Early #NSCLC RT and bring others into the discussion‼️

13 10 26 3K 4

View Details

Nehemias Guevara-Rodriguez @NehemiasGuevar5

a month ago

Join us tomorrow at 8 PM ET for a deep dive into early-stage #NSCLC and #NeoADAURA @TumorBoardTues @NarjustFlorezMD @Florez_Lab @OncBrothers @COlazagasti @dominicandoc2 @oncodaily @Arthur_Aung @guicorreiamd @IMG_Oncologists @Shuai_WangOnc @HyeinJeon_MD @TejaVorugantiMD @OncLive

#TumorBoardTuesday @TumorBoardTues

a month ago

13 10 26 3K 4

0 8 16 1K 0

View Details

Arthur Aung @Arthur_Aung

a month ago

Honored to contribute to the discussion on thyroid cancer in 2026. Thank you to @oncodaily @NagashreeSeeth1 @DrMLChua @amanda_psyrri for organizing the summit.